

## PURPOSE

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## PRODUCT

<b>Name</b>	Tracker Certificate – AtonRâ Healthcare M&A
<b>Identifier</b>	ISIN Code: XS1365787826
<b>Manufacturer</b>	Natixis SA (Issuer: Natixis SA)
<b>Competent authority</b>	Autorité des Marchés Financiers and Autorité de Contrôle Prudentiel et de Résolution
<b>Contacting the manufacturer</b>	<a href="http://www.natixis.com">www.natixis.com</a> / Call +33(1)58.55.47.00 for more information
<b>KID Production Date</b>	19 February 2018

You are about to purchase a product that is not simple and may be difficult to understand

## WHAT IS THIS PRODUCT?

**Type** The product is in the form of a debt instrument governed by English law.

**Objectives** The objective of the product is to provide exposure to an underlying index (the Index). The product tracks the performance of the Index adjusted for any applicable fees and costs on a daily basis. The Index composition is based on a dynamic investment allocation process monitored by the Index Advisor in accordance with the Index Advisor agreement between the Index Advisor and the Index Sponsor. The capital invested in the product is fully at risk. When the performance of the Index is positive, the value of the product will rise by the Index increase in value (excluding fees and costs). Conversely, when the performance of the Index is negative, the value of the product will fall by the Index decrease in value (excluding fees and costs).

The Issuer may early redeem the product (the Issuer Call) or upon the occurrence of the Event Issuer Call with prior information notice equal to the relevant Notice Period.

**Redemption on the Maturity Date:** if the product is not redeemed before the Maturity Date, then you will receive the Nominal Amount multiplied by the Index Performance on the Valuation Date.

**Redemption in case of Issuer Call or Event Issuer Call:** you will receive on the relevant Optional Redemption Date, the Nominal amount multiplied by the Index Performance on the relevant Early Valuation Date.


### Key Dates, Values and Definitions

All determinations and observations will be made by the Calculation Agent. All dates may be subject to adjustment for non-business days and market disruption events.

- **Index:** Natixis AtonRâ Healthcare M&A Index
- **Bloomberg code of the Index:** NXRHEMA Index
- **Index Sponsor:** Natixis
- **Index Advisor:** AtonRâ Partners S.A.
- **Calculation Agent:** Natixis
- **Dealer:** Natixis
- **Index Investment Universe:** shares of companies involved in healthcare which are to benefit from M&A potential (which may include units of exchange traded funds) and cash.
- **Closing Value:** the value of the Index as of the close of trading on a given scheduled trading day
- **Index Performance:** the Closing Value of the Index on any given date divided by the Initial Level.
- **Nominal Amount:** USD 1,000
- **Issue Price:** 100% of the Nominal Amount
- **Initial Level:** 100 points
- **Notice Period:** 30 scheduled trading days in case of an Issuer Call or 4 scheduled trading days in case of an Event Issuer Call
- **Event Issuer Call:** the outstanding principal amount of the Certificates falls below USD 1,000,000
- **Dates:**
  - **Issue Date:** 29/09/2017
  - **Maturity Date:** 29/09/2027
  - **Valuation Date:** 15/09/2027
  - **Early Valuation Date:** the notification date in case of Event Issuer Call or 30 scheduled trading days following the notification date in case of Issuer Call.
  - **Optional Redemption Date:** maximum 10 scheduled trading days from the Early Valuation Date

### Early redemption and adjustments

The terms of the product provide that in certain defined events, in addition to those described above, occur (principally but not



exclusively in relation to any Underlying, or the Issuer of the product (which may include the discontinuation of the Issuer's ability to carry out the necessary hedging transactions), adjustments may be made to the terms of the product to account for the relevant event or the product may be early redeemed. The amount paid on any early redemption may be less than the amount originally invested.

### Intended retail investor

This product is intended for investors who:

- have sufficient knowledge and experience in products such as the one described in this document
- are willing and able to bear a potentially total loss of capital and accept the credit risk of the Issuer
- have a risk tolerance consistent with the summary risk indicator in this document
- have capital growth objectives
- have a horizon consistent with the term of this product

## WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?

### Summary Risk Indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because the Issuer is not able to pay you. We have classified this product as 5 out of 7 a medium-high risk class. This takes into consideration two elements: 1) the market risk - that rates the potential losses from future performance at a medium-high level; and 2) the credit risk which estimates that poor market conditions are very unlikely to impact the capacity of the Issuer to pay you. **You will receive payments in the product's currency, which may be different from your domestic currency. In this case, be aware of currency risk. The final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.** This product does not include any protection from future market performance so you could lose some or the entire amount you have already paid in. If the Issuer is not able to pay you what is owed, you could lose your entire investment.

*The risk indicator assumes you keep the product until 19/02/2020. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back.*

### Performance Scenarios

Investment USD 10,000			
Scenarios		1 year	2 years (Recommended holding period)
Stress scenario	What you might get back after costs	<b>USD 6,414.40</b>	<b>USD 5,243.21</b>
	Average return each year	-35.86%	-27.59%
Unfavourable scenario	What you might get back after costs	<b>USD 9,879.95</b>	<b>USD 11,429.25</b>
	Average return each year	-1.20%	6.91%
Moderate scenario	What you might get back after costs	<b>USD 12,940.29</b>	<b>USD 16,730.92</b>
	Average return each year	29.40%	29.35%
Favourable scenario	What you might get back after costs	<b>USD 16,901.45</b>	<b>USD 24,423.77</b>
	Average return each year	69.01%	56.28%

*This table shows the money you could get back over the next 2 years, under different scenarios, assuming that you invest USD 10,000. The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the investment. The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you.*

*The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.*


### WHAT HAPPENS IF NATIXIS IS UNABLE TO PAY OUT?

If the Issuer becomes subject to resolution measures in the form of the bail-in tool ("bail-in"), your claim may be reduced to zero, converted into equity or its maturity may be postponed. This product is not protected by any investor compensation or guarantee scheme. If the Issuer is unable to make a payment and/or is in default, you may lose some or your entire invested amount and any payment may be delayed.

### WHAT ARE THE COSTS?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for 2 different holding periods. They include potential early exit penalties. The figures assume you invest USD 10,000. The figures are estimates and may change in the future.



## Costs over time

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Investment USD 10,000		
Scenarios	If you cash in after 1 year	If you cash in at the end of the recommended holding period
Total costs	USD 800	USD 1.659
Impact on return (RIY) per year	8.00%	8.01%

## Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period;
- The meaning of the different cost categories.

This table shows the impact on Investment return per year			
<b>One-off costs</b>	Entry costs	0.00%	The impact of the costs already included in the price.
	Exit costs	0.00%	The impact of the costs of exiting your investment when it matures.
<b>Ongoing costs</b>	Portfolio transaction costs	0.94%	The impact of the costs of us buying and selling underlying investments for the product.
	Other ongoing costs	2.14%	The impact of the costs that we take each year for managing your investments.
<b>Incidental costs</b>	Performance fees	4.89%	The impact of the performance fee.
	Carried interests	0.00%	Not applicable

## HOW LONG SHOULD I HOLD IT AND CAN I TAKE MY MONEY OUT EARLY?

Recommended holding period: 2 years. The recommended holding period corresponds with the maturity date of the product, as the product is designed to be held until then. Any recommendation regarding the holding period may be irrelevant for a speculative investor. For investors purchasing the product for hedging purposes the holding period depends on the holding period of the underlying risk.

Under normal market conditions, Natixis ensures a secondary market during the life of the product with a maximum bid-offer spread of 0.10%. If you want to sell this product before the Maturity Date, the price of the product will depend on market parameters at the time you wish to sell. In this case you may sustain a partial or total capital loss. More information available upon request.

## HOW CAN I COMPLAIN?

For any claim relating to the service, you have received linked to this product please contact your usual adviser. If you wish to complain at any time about this product, or the service you have received, you may do so by contacting your usual adviser or Natixis claims department at: [www.natixis.com/natixis/jcms/tpaz5\\_55348/en](http://www.natixis.com/natixis/jcms/tpaz5_55348/en) or in writing to NATIXIS Service de traitement des réclamations - Banque de Grande Clientèle 47 Quai d'Austerlitz 75013 Paris or by email to [reclamations-bgc@natixis.com](mailto:reclamations-bgc@natixis.com)

## OTHER RELEVANT INFORMATION

The prospectus (a base prospectus as may be supplemented from time to time and as supplemented by the final terms or a prospectus and, as the case may be, any applicable summary section thereof) under which the product is issued is available free of charge from the manufacturer at the following address: Natixis Equity Solutions, 47 quai d'Austerlitz, 75013 Paris - France and may be available on the following website of the manufacturer [www.equitysolutions.natixis.fr](http://www.equitysolutions.natixis.fr). The information contained in this Key Information Document (KID) does not constitute a recommendation to buy or sell the product and is no substitute for individual consultation with the investor's bank or advisor. You can obtain further information about this product from your financial advisor. This KID is a pre-contractual document which gives you the main information about the product (characteristics, risks, costs ...). If you make a transaction, a transaction confirmation will be sent to you after the transaction.